Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Hutchmed China Ltd ADR (HCM)

Hutchmed China Ltd ADR (HCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,494,520
  • Shares Outstanding, K 174,320
  • Annual Sales, $ 838,000 K
  • Annual Income, $ 100,780 K
  • EBIT $ 0 M
  • EBITDA $ 27 M
  • 60-Month Beta 0.78
  • Price/Sales 3.04
  • Price/Cash Flow 23.36
  • Price/Book 3.39

Options Overview Details

View History
  • Implied Volatility 96.35% ( -52.79%)
  • Historical Volatility 46.26%
  • IV Percentile 65%
  • IV Rank 55.11%
  • IV High 152.40% on 12/18/24
  • IV Low 27.53% on 07/12/24
  • Put/Call Vol Ratio 3.86
  • Today's Volume 34
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 329
  • Open Int (30-Day) 326

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.00 +2.21%
on 12/20/24
18.57 -22.94%
on 11/27/24
-3.65 (-20.32%)
since 11/20/24
3-Month
14.00 +2.21%
on 12/20/24
21.50 -33.44%
on 10/23/24
-3.07 (-17.66%)
since 09/20/24
52-Week
11.93 +19.91%
on 02/05/24
21.92 -34.72%
on 05/10/24
-2.52 (-14.97%)
since 12/20/23

Most Recent Stories

More News
HUTCHMED Granted Breakthrough Therapy Designation for Combination of ORPATHYS® and TAGRISSO® in Treating Advanced Non-Small Cell Lung Cancer

HUTCHMED announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® combination for advanced lung cancer.Quiver AI SummaryHUTCHMED has received Breakthrough Therapy Designation from...

HCM : 14.31 (-2.05%)
HUTCHMED and Innovent Announce First Regulatory Approval of Fruquintinib Combination Therapy with Sintilimab for Advanced Endometrial Cancer in China

HUTCHMED and Innovent announced conditional approval for fruquintinib plus sintilimab combination therapy for advanced endometrial cancer in China.Quiver AI SummaryHUTCHMED and Innovent Biologics have...

HCM : 14.31 (-2.05%)
HUTCHMED Announces Renewal of Inclusion for ORPATHYS® in China's National Reimbursement Drug List Effective January 1, 2025

HUTCHMED announces ORPATHYS® will remain on China's National Reimbursement Drug List following contract renewal with NHSA.Quiver AI SummaryHUTCHMED (China) Limited announced that ORPATHYS® (savolitinib)...

HCM : 14.31 (-2.05%)
HUTCHMED Receives Milestone Payment as FRUZAQLA® Launches in Japan for Metastatic Colorectal Cancer

HUTCHMED announces FRUZAQLA® launch in Japan for metastatic colorectal cancer after regulatory approval and milestone payment from Takeda.Quiver AI SummaryHUTCHMED has announced the approval and launch...

HCM : 14.31 (-2.05%)
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
HCM : 14.31 (-2.05%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
ELVN : 22.47 (-1.75%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
HCM : 14.31 (-2.05%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
ELVN : 22.47 (-1.75%)
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...

HCM : 14.31 (-2.05%)
HCM.LN : 237.000 (-0.42%)
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...

HCM : 14.31 (-2.05%)
HCM.LN : 237.000 (-0.42%)
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...

HCM : 14.31 (-2.05%)
HCM.LN : 237.000 (-0.42%)
HUTCHMED Reports 2022 Interim Results and Provides Business Updates

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...

HCM : 14.31 (-2.05%)
HCM.LN : 237.000 (-0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

HUTCHMED Limited is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. HUTCHMED Limited, formerly known as HUTCHMED...

See More

Key Turning Points

3rd Resistance Point 15.14
2nd Resistance Point 14.85
1st Resistance Point 14.58
Last Price 14.31
1st Support Level 14.02
2nd Support Level 13.73
3rd Support Level 13.46

See More

52-Week High 21.92
Fibonacci 61.8% 18.11
Fibonacci 50% 16.93
Fibonacci 38.2% 15.75
Last Price 14.31
52-Week Low 11.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar